Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3122 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Microbix to acquire urokinase from ImaRx

Under terms of the agreement, Microbix will acquire the urokinase product and related assets for an upfront payment of $12 million plus an additional $5 million upon achievement

Enzon to spin off biotechnology business

Following the spin-off of the biotechnology company, Enzon will retain the current marketed products of Abelcet, Adagen, DepoCyt and Oncaspar, the rights to current PEG royalty revenues, including

Lipid Sciences granted two new patents

The first of these patents covers the company’s HDL Selective Delipidation technology. HDL Selective Delipidation modifies naturally occurring HDL resulting in the creation of a substantially more effective